OraSure Technologies Announces Significant Additions to Management Team

BETHLEHEM, Pa., Aug 31, 2001 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq NM: OSUR) today announced two key additions to its management team - - Salvatore Salamone as Senior Vice President, Development, and Eve Damiano as Vice President, Regulatory Affairs.

Dr. Salamone joins OraSure Technologies with 17 years of research and development experience at Roche Diagnostics. Dr. Salamone's most recent position at Roche was Vice President, Research and Development, where he was responsible for all North American research and development efforts for the laboratory systems division.

Dr. Salamone's efforts resulted in the launch of seven major product lines and 200 instrument applications, including Roche's market-leading on-site urine drug testing products.

Ms. Damiano brings to OraSure Technologies more than 19 years of professional experience spanning research and development, manufacturing, quality, and 12 years in regulatory affairs.

Ms. Damiano's expertise was primarily developed during her tenure at Centocor and MedImmune Oncology (the former US Bioscience), and includes extensive experience in the development of regulatory strategies and management of applications to support clinical trials and marketing of FDA regulated products.

"As OraSure Technologies continues to grow and expands its projects and product lines, it is critical that we build the managerial team to handle our growth potential. Sal and Eve bring important skill sets to the team. We are already seeing the benefits of having them at the Company and look forward to the contributions they will make," said Robert D. Thompson, OraSure Technologies' Chief Executive Officer.

    About OraSure Technologies

OraSure Technologies, Inc. develops, manufactures and markets medical devices and diagnostic products for use by public- and private-sector clients, clinical laboratories, physicians' offices and workplace testing.

OraSure Technologies is the leading supplier of oral fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV. In addition, the company supplies oral fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to www.orasure.com.

CONTACT:          OraSure Technologies
                  Rich Hooper, 610/882-1820
                  investorinfo@orasure.com